Hormone-blocking treatment plus radiation to reduce breast cancer spread to the brain
Mechanisms of endocrine therapy and radiation synergism to decrease brain metastases
This project looks at whether combining hormone-blocking drugs with radiation helps the immune system stop breast cancer from spreading to the brain in women, especially younger patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11180134 on NIH RePORTER |
What this research studies
Researchers at the University of Colorado will study how the hormone estradiol affects brain support cells and the immune response around tumors using laboratory and animal models. They plan to give endocrine therapies (like aromatase inhibitors) together with brain radiation in immunocompetent models to see if the combination boosts antigen presentation and immune cell recruitment to block brain metastases. The team will examine astrocytes and tumor markers such as S100A4 and IRF with molecular analyses of tumor and brain tissue. The goal is to use these lab findings to guide combining existing FDA-approved hormone drugs with radiation for patients with breast cancer brain metastases.
Who could benefit from this research
Good fit: Women with metastatic breast cancer who are at risk of or already have brain metastases—especially younger or premenopausal patients and those with tumors influenced by estrogen signaling—would be the most relevant group.
Not a fit: Patients whose tumors are not hormone-sensitive, who cannot receive radiation, or who have non-breast cancers are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could lead to new ways to use existing hormone drugs plus radiation to reduce or slow brain metastases and improve outcomes for breast cancer patients.
How similar studies have performed: Preclinical studies and the team's preliminary data show promising synergy between endocrine therapy and radiation in immune-competent models, but clinical benefits for patients with brain metastases remain unproven.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Cittelly, Diana M. — University of Colorado Denver
- Study coordinator: Cittelly, Diana M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.